Tilray Q4 revenue rises 25% on the back of international medical cannabis
TLRY•Outlook
- Tilray expects fiscal 2027 adjusted EBITDA of $68 mln to $75 mln
- Company anticipates annual revenue above $1 bln in fiscal 2027
- Tilray says regulatory uncertainty persists in U.S. cannabis market
Overview
- Canada-U.S. cannabis and beverage firm's fiscal Q4 revenue rose 25% yr/yr
- Adjusted EPS for fiscal Q4 rose to $0.05 from $0.01 a year ago
- Company posted a net loss in Q4, mainly due to non-cash charges
Key details
| Metric | Actual |
|---|---|
| Q4 Revenue | $281.71 mln |
| Q4 Loss Per Share | $0.43 |
| Q4 Adjusted Net Income | $5.30 mln |
| Q4 Net Loss | $37.93 mln |
The one available analyst rating on the shares is "hold". Wall Street's median 12-month price target for Tilray Brands Inc is C$7.25, about 26.7% above its July 27 closing price of C$5.72.
Result drivers
- International medical cannabis - Co said international medical cannabis revenue rose 34% for the year, driven by its European platform and pharmaceutical distribution network
